Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced it has received Investigational Device Exemption (IDE) approval from the FDA for a subsequent multicenter study, PROACTIVE-HF 2, which will evaluate the …
Trending at Lumira Ventures
Endotronix Extends Positive Outcomes with 12-month Data Release from the SIRONA 2 Trial for Remote Heart Failure Management Using the Cordella Pulmonary Artery Sensor
The study met secondary study endpoints and long-term sensor use was associated with significant improvements in patient quality-of-life metrics and low event rates for heart failure hospitalization and death. Endotronix, Inc., a digital health and medical technology company dedicated to advancing …
Endotronix Announces Enrollment Completion of PROACTIVE-HF Pivotal Trial
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced its PROACTIVE-HF pivotal study successfully completed enrollment. Designed to evaluate the safety and efficacy of the Cordella™ Pulmonary Artery (PA) Sensor, the data will support …
Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal …
Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors
LISLE, IL – MARCH 2, 2021 – Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board …
Endotronix Enrolls First Patients in PROACTIVE-HF Pivotal Trial
LISLE, Ill. /PRNewswire/ — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF pivotal trial. The trial is a pre-market …
Endotronix Presents Positive Data from the SIRONA First-in-Human Trial for the Cordella™ PA Pressure Sensor System
LISLE, Ill., Nov. 18, 2019 /PRNewswire/ — Endotronix Inc., a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella™ Pulmonary Artery (PA) Pressure Sensor System (Cordella Sensor). Data …
Endotronix Announces Partnership with Tyndall National Institute to Advance Chronic Disease Management
PRNewswire — Endotronix Ireland Limited, a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced today an Enterprise Ireland Industry Partnership project is a collaboration with Tyndall National Institute, a leading European Deep Tech research center in integrated …
Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution
LISLE, IL – Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The expansion syndicate …
Endotronix Receives conditional IDE approval from the US Food & Drug Administration
Related Article: Endotronix Receives 13485:2016 certification from the British Standards Institution (BSI) for its Quality Management System LISLE, Ill., Aug. 1, 2019 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced …
Endotronix Enrolls First Patient in SIRONA II CE Mark Trial
Study to support European clearance of Cordella™ Pulmonary Artery Sensor System for treatment of patients with chronic heart failure LISLE, IL – Endotronix Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced …
Endotronix Receives ISO 13485:2016 Certification
LISLE, Ill., April 24, 2019 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced that the company received ISO 13485:2016 certification from British Standards Institution (BSI) for its Quality Management …
Endotronix Hires Industry Veteran Jim Yearick as Senior Vice President of Sales and Marketing
LISLE, Ill., Jan. 3, 2019 – Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced that industry veteran Jim Yearick has joined the executive leadership team as Senior Vice President …
Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure
Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million. The round was led by LSP, investing from its LSP Health Economics Fund …
Endotronix Joins American Heart Association’s Center for Health Technology & Innovation to Broaden the Use of Guideline-Based Care for Heart Failure Patients
LISLE, Ill., June 28, 2018 /PRNewswire/ — Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced they have joined the American Heart Association’s Center for Health Technology & Innovation’s (CHTI) Innovators Network. The collaboration allows Endotronix …
- Page 1 of 2
- 1
- 2